Report error Found 64 Enz. Inhib. hit(s) with all data for entry = 13026
Affinity DataIC50: 5.60nMAssay Description:a) BI-2852 was used as a positive control, with its stock solution as the first dilution point, followed by a 3-fold dilution, making a total of 10+0...More data for this Ligand-Target Pair
TargetGTPase KRas [G12D]/Son of sevenless homolog 1 [564-1049](Human)
Shanghai Pharmaceuticals Holding Co.
US Patent
Shanghai Pharmaceuticals Holding Co.
US Patent
Affinity DataIC50: 5.75nMAssay Description:a) BI-2852 was used as a positive control, with its stock solution as the first dilution point, followed by a 3-fold dilution, making a total of 10+0...More data for this Ligand-Target Pair
TargetGTPase KRas [G12D]/RAF proto-oncogene serine/threonine-protein kinase(Human)
Shanghai Pharmaceuticals Holding Co.
US Patent
Shanghai Pharmaceuticals Holding Co.
US Patent
Affinity DataIC50: 5.81nMAssay Description:a) BI-2852 was used as a positive control, with its stock solution as the first dilution point, followed by a 3-fold dilution, making a total of 10+0...More data for this Ligand-Target Pair
TargetGTPase KRas [G12D]/Son of sevenless homolog 1 [564-1049](Human)
Shanghai Pharmaceuticals Holding Co.
US Patent
Shanghai Pharmaceuticals Holding Co.
US Patent
Affinity DataIC50: 6.54nMAssay Description:a) BI-2852 was used as a positive control, with its stock solution as the first dilution point, followed by a 3-fold dilution, making a total of 10+0...More data for this Ligand-Target Pair
TargetGTPase KRas [G12D]/Son of sevenless homolog 1 [564-1049](Human)
Shanghai Pharmaceuticals Holding Co.
US Patent
Shanghai Pharmaceuticals Holding Co.
US Patent
Affinity DataIC50: 6.72nMAssay Description:a) BI-2852 was used as a positive control, with its stock solution as the first dilution point, followed by a 3-fold dilution, making a total of 10+0...More data for this Ligand-Target Pair
TargetGTPase KRas [G12D]/Son of sevenless homolog 1 [564-1049](Human)
Shanghai Pharmaceuticals Holding Co.
US Patent
Shanghai Pharmaceuticals Holding Co.
US Patent
Affinity DataIC50: 7.21nMAssay Description:a) BI-2852 was used as a positive control, with its stock solution as the first dilution point, followed by a 3-fold dilution, making a total of 10+0...More data for this Ligand-Target Pair
TargetGTPase KRas [G12D]/Son of sevenless homolog 1 [564-1049](Human)
Shanghai Pharmaceuticals Holding Co.
US Patent
Shanghai Pharmaceuticals Holding Co.
US Patent
Affinity DataIC50: 7.5nMAssay Description:a) BI-2852 was used as a positive control, with its stock solution as the first dilution point, followed by a 3-fold dilution, making a total of 10+0...More data for this Ligand-Target Pair
TargetGTPase KRas [G12D]/Son of sevenless homolog 1 [564-1049](Human)
Shanghai Pharmaceuticals Holding Co.
US Patent
Shanghai Pharmaceuticals Holding Co.
US Patent
Affinity DataIC50: 7.55nMAssay Description:a) BI-2852 was used as a positive control, with its stock solution as the first dilution point, followed by a 3-fold dilution, making a total of 10+0...More data for this Ligand-Target Pair
TargetGTPase KRas [G12D]/RAF proto-oncogene serine/threonine-protein kinase(Human)
Shanghai Pharmaceuticals Holding Co.
US Patent
Shanghai Pharmaceuticals Holding Co.
US Patent
Affinity DataIC50: 8.22nMAssay Description:a) BI-2852 was used as a positive control, with its stock solution as the first dilution point, followed by a 3-fold dilution, making a total of 10+0...More data for this Ligand-Target Pair
TargetGTPase KRas [G12D]/Son of sevenless homolog 1 [564-1049](Human)
Shanghai Pharmaceuticals Holding Co.
US Patent
Shanghai Pharmaceuticals Holding Co.
US Patent
Affinity DataIC50: 8.81nMAssay Description:a) BI-2852 was used as a positive control, with its stock solution as the first dilution point, followed by a 3-fold dilution, making a total of 10+0...More data for this Ligand-Target Pair
TargetGTPase KRas [G12D]/Son of sevenless homolog 1 [564-1049](Human)
Shanghai Pharmaceuticals Holding Co.
US Patent
Shanghai Pharmaceuticals Holding Co.
US Patent
Affinity DataIC50: 9.95nMAssay Description:a) BI-2852 was used as a positive control, with its stock solution as the first dilution point, followed by a 3-fold dilution, making a total of 10+0...More data for this Ligand-Target Pair
Affinity DataIC50: 11.4nMAssay Description:a) BI-2852 was used as a positive control, with its stock solution as the first dilution point, followed by a 3-fold dilution, making a total of 10+0...More data for this Ligand-Target Pair
TargetGTPase KRas [G12D]/Son of sevenless homolog 1 [564-1049](Human)
Shanghai Pharmaceuticals Holding Co.
US Patent
Shanghai Pharmaceuticals Holding Co.
US Patent
Affinity DataIC50: 11.7nMAssay Description:a) BI-2852 was used as a positive control, with its stock solution as the first dilution point, followed by a 3-fold dilution, making a total of 10+0...More data for this Ligand-Target Pair
TargetGTPase KRas [G12D]/Son of sevenless homolog 1 [564-1049](Human)
Shanghai Pharmaceuticals Holding Co.
US Patent
Shanghai Pharmaceuticals Holding Co.
US Patent
Affinity DataIC50: 11.9nMAssay Description:a) BI-2852 was used as a positive control, with its stock solution as the first dilution point, followed by a 3-fold dilution, making a total of 10+0...More data for this Ligand-Target Pair
TargetGTPase KRas [G12D]/RAF proto-oncogene serine/threonine-protein kinase(Human)
Shanghai Pharmaceuticals Holding Co.
US Patent
Shanghai Pharmaceuticals Holding Co.
US Patent
Affinity DataIC50: 12.2nMAssay Description:a) BI-2852 was used as a positive control, with its stock solution as the first dilution point, followed by a 3-fold dilution, making a total of 10+0...More data for this Ligand-Target Pair
TargetGTPase KRas [G12D]/Son of sevenless homolog 1 [564-1049](Human)
Shanghai Pharmaceuticals Holding Co.
US Patent
Shanghai Pharmaceuticals Holding Co.
US Patent
Affinity DataIC50: 12.7nMAssay Description:a) BI-2852 was used as a positive control, with its stock solution as the first dilution point, followed by a 3-fold dilution, making a total of 10+0...More data for this Ligand-Target Pair
TargetGTPase KRas [G12D]/Son of sevenless homolog 1 [564-1049](Human)
Shanghai Pharmaceuticals Holding Co.
US Patent
Shanghai Pharmaceuticals Holding Co.
US Patent
Affinity DataIC50: 13.4nMAssay Description:a) BI-2852 was used as a positive control, with its stock solution as the first dilution point, followed by a 3-fold dilution, making a total of 10+0...More data for this Ligand-Target Pair
TargetGTPase KRas [G12D]/Son of sevenless homolog 1 [564-1049](Human)
Shanghai Pharmaceuticals Holding Co.
US Patent
Shanghai Pharmaceuticals Holding Co.
US Patent
Affinity DataIC50: 13.5nMAssay Description:a) BI-2852 was used as a positive control, with its stock solution as the first dilution point, followed by a 3-fold dilution, making a total of 10+0...More data for this Ligand-Target Pair
TargetGTPase KRas [G12D]/Son of sevenless homolog 1 [564-1049](Human)
Shanghai Pharmaceuticals Holding Co.
US Patent
Shanghai Pharmaceuticals Holding Co.
US Patent
Affinity DataIC50: 14.5nMAssay Description:a) BI-2852 was used as a positive control, with its stock solution as the first dilution point, followed by a 3-fold dilution, making a total of 10+0...More data for this Ligand-Target Pair
TargetGTPase KRas [G12D]/Son of sevenless homolog 1 [564-1049](Human)
Shanghai Pharmaceuticals Holding Co.
US Patent
Shanghai Pharmaceuticals Holding Co.
US Patent
Affinity DataIC50: 15.2nMAssay Description:a) BI-2852 was used as a positive control, with its stock solution as the first dilution point, followed by a 3-fold dilution, making a total of 10+0...More data for this Ligand-Target Pair
TargetGTPase KRas [G12D]/Son of sevenless homolog 1 [564-1049](Human)
Shanghai Pharmaceuticals Holding Co.
US Patent
Shanghai Pharmaceuticals Holding Co.
US Patent
Affinity DataIC50: 15.2nMAssay Description:a) BI-2852 was used as a positive control, with its stock solution as the first dilution point, followed by a 3-fold dilution, making a total of 10+0...More data for this Ligand-Target Pair
TargetGTPase KRas [G12D]/Son of sevenless homolog 1 [564-1049](Human)
Shanghai Pharmaceuticals Holding Co.
US Patent
Shanghai Pharmaceuticals Holding Co.
US Patent
Affinity DataIC50: 15.3nMAssay Description:a) BI-2852 was used as a positive control, with its stock solution as the first dilution point, followed by a 3-fold dilution, making a total of 10+0...More data for this Ligand-Target Pair
TargetGTPase KRas [G12D]/Son of sevenless homolog 1 [564-1049](Human)
Shanghai Pharmaceuticals Holding Co.
US Patent
Shanghai Pharmaceuticals Holding Co.
US Patent
Affinity DataIC50: 15.7nMAssay Description:a) BI-2852 was used as a positive control, with its stock solution as the first dilution point, followed by a 3-fold dilution, making a total of 10+0...More data for this Ligand-Target Pair
TargetGTPase KRas [G12D]/Son of sevenless homolog 1 [564-1049](Human)
Shanghai Pharmaceuticals Holding Co.
US Patent
Shanghai Pharmaceuticals Holding Co.
US Patent
Affinity DataIC50: 15.7nMAssay Description:a) BI-2852 was used as a positive control, with its stock solution as the first dilution point, followed by a 3-fold dilution, making a total of 10+0...More data for this Ligand-Target Pair
TargetGTPase KRas [G12D]/RAF proto-oncogene serine/threonine-protein kinase(Human)
Shanghai Pharmaceuticals Holding Co.
US Patent
Shanghai Pharmaceuticals Holding Co.
US Patent
Affinity DataIC50: 16.4nMAssay Description:a) BI-2852 was used as a positive control, with its stock solution as the first dilution point, followed by a 3-fold dilution, making a total of 10+0...More data for this Ligand-Target Pair
TargetGTPase KRas [G12D]/Son of sevenless homolog 1 [564-1049](Human)
Shanghai Pharmaceuticals Holding Co.
US Patent
Shanghai Pharmaceuticals Holding Co.
US Patent
Affinity DataIC50: 16.7nMAssay Description:a) BI-2852 was used as a positive control, with its stock solution as the first dilution point, followed by a 3-fold dilution, making a total of 10+0...More data for this Ligand-Target Pair
TargetGTPase KRas [G12D]/Son of sevenless homolog 1 [564-1049](Human)
Shanghai Pharmaceuticals Holding Co.
US Patent
Shanghai Pharmaceuticals Holding Co.
US Patent
Affinity DataIC50: 17.2nMAssay Description:a) BI-2852 was used as a positive control, with its stock solution as the first dilution point, followed by a 3-fold dilution, making a total of 10+0...More data for this Ligand-Target Pair
TargetGTPase KRas [G12D]/Son of sevenless homolog 1 [564-1049](Human)
Shanghai Pharmaceuticals Holding Co.
US Patent
Shanghai Pharmaceuticals Holding Co.
US Patent
Affinity DataIC50: 17.4nMAssay Description:a) BI-2852 was used as a positive control, with its stock solution as the first dilution point, followed by a 3-fold dilution, making a total of 10+0...More data for this Ligand-Target Pair
TargetGTPase KRas [G12D]/Son of sevenless homolog 1 [564-1049](Human)
Shanghai Pharmaceuticals Holding Co.
US Patent
Shanghai Pharmaceuticals Holding Co.
US Patent
Affinity DataIC50: 18.3nMAssay Description:a) BI-2852 was used as a positive control, with its stock solution as the first dilution point, followed by a 3-fold dilution, making a total of 10+0...More data for this Ligand-Target Pair
TargetGTPase KRas [G12D]/Son of sevenless homolog 1 [564-1049](Human)
Shanghai Pharmaceuticals Holding Co.
US Patent
Shanghai Pharmaceuticals Holding Co.
US Patent
Affinity DataIC50: 18.5nMAssay Description:a) BI-2852 was used as a positive control, with its stock solution as the first dilution point, followed by a 3-fold dilution, making a total of 10+0...More data for this Ligand-Target Pair
TargetGTPase KRas [G12D]/RAF proto-oncogene serine/threonine-protein kinase(Human)
Shanghai Pharmaceuticals Holding Co.
US Patent
Shanghai Pharmaceuticals Holding Co.
US Patent
Affinity DataIC50: 19.5nMAssay Description:a) BI-2852 was used as a positive control, with its stock solution as the first dilution point, followed by a 3-fold dilution, making a total of 10+0...More data for this Ligand-Target Pair
TargetGTPase KRas [G12D]/Son of sevenless homolog 1 [564-1049](Human)
Shanghai Pharmaceuticals Holding Co.
US Patent
Shanghai Pharmaceuticals Holding Co.
US Patent
Affinity DataIC50: 21.3nMAssay Description:a) BI-2852 was used as a positive control, with its stock solution as the first dilution point, followed by a 3-fold dilution, making a total of 10+0...More data for this Ligand-Target Pair
TargetGTPase KRas [G12D]/Son of sevenless homolog 1 [564-1049](Human)
Shanghai Pharmaceuticals Holding Co.
US Patent
Shanghai Pharmaceuticals Holding Co.
US Patent
Affinity DataIC50: 21.5nMAssay Description:a) BI-2852 was used as a positive control, with its stock solution as the first dilution point, followed by a 3-fold dilution, making a total of 10+0...More data for this Ligand-Target Pair
TargetGTPase KRas [G12D]/RAF proto-oncogene serine/threonine-protein kinase(Human)
Shanghai Pharmaceuticals Holding Co.
US Patent
Shanghai Pharmaceuticals Holding Co.
US Patent
Affinity DataIC50: 24nMAssay Description:a) BI-2852 was used as a positive control, with its stock solution as the first dilution point, followed by a 3-fold dilution, making a total of 10+0...More data for this Ligand-Target Pair
TargetGTPase KRas [G12D]/Son of sevenless homolog 1 [564-1049](Human)
Shanghai Pharmaceuticals Holding Co.
US Patent
Shanghai Pharmaceuticals Holding Co.
US Patent
Affinity DataIC50: 28.2nMAssay Description:a) BI-2852 was used as a positive control, with its stock solution as the first dilution point, followed by a 3-fold dilution, making a total of 10+0...More data for this Ligand-Target Pair
TargetGTPase KRas [G12D]/RAF proto-oncogene serine/threonine-protein kinase(Human)
Shanghai Pharmaceuticals Holding Co.
US Patent
Shanghai Pharmaceuticals Holding Co.
US Patent
Affinity DataIC50: 32.5nMAssay Description:a) BI-2852 was used as a positive control, with its stock solution as the first dilution point, followed by a 3-fold dilution, making a total of 10+0...More data for this Ligand-Target Pair
TargetGTPase KRas [G12D]/Son of sevenless homolog 1 [564-1049](Human)
Shanghai Pharmaceuticals Holding Co.
US Patent
Shanghai Pharmaceuticals Holding Co.
US Patent
Affinity DataIC50: 45.6nMAssay Description:a) BI-2852 was used as a positive control, with its stock solution as the first dilution point, followed by a 3-fold dilution, making a total of 10+0...More data for this Ligand-Target Pair
TargetGTPase KRas [G12D]/RAF proto-oncogene serine/threonine-protein kinase(Human)
Shanghai Pharmaceuticals Holding Co.
US Patent
Shanghai Pharmaceuticals Holding Co.
US Patent
Affinity DataIC50: 46.8nMAssay Description:a) BI-2852 was used as a positive control, with its stock solution as the first dilution point, followed by a 3-fold dilution, making a total of 10+0...More data for this Ligand-Target Pair
Affinity DataIC50: 61.2nMAssay Description:a) BI-2852 was used as a positive control, with its stock solution as the first dilution point, followed by a 3-fold dilution, making a total of 10+0...More data for this Ligand-Target Pair
Affinity DataIC50: 79.6nMAssay Description:a) BI-2852 was used as a positive control, with its stock solution as the first dilution point, followed by a 3-fold dilution, making a total of 10+0...More data for this Ligand-Target Pair
TargetGTPase KRas [G12D]/RAF proto-oncogene serine/threonine-protein kinase(Human)
Shanghai Pharmaceuticals Holding Co.
US Patent
Shanghai Pharmaceuticals Holding Co.
US Patent
Affinity DataIC50: 84.8nMAssay Description:a) BI-2852 was used as a positive control, with its stock solution as the first dilution point, followed by a 3-fold dilution, making a total of 10+0...More data for this Ligand-Target Pair
TargetGTPase KRas [G12D]/Son of sevenless homolog 1 [564-1049](Human)
Shanghai Pharmaceuticals Holding Co.
US Patent
Shanghai Pharmaceuticals Holding Co.
US Patent
Affinity DataIC50: 115nMAssay Description:a) BI-2852 was used as a positive control, with its stock solution as the first dilution point, followed by a 3-fold dilution, making a total of 10+0...More data for this Ligand-Target Pair
Affinity DataIC50: 233nMAssay Description:a) BI-2852 was used as a positive control, with its stock solution as the first dilution point, followed by a 3-fold dilution, making a total of 10+0...More data for this Ligand-Target Pair
Affinity DataIC50: 246nMAssay Description:a) BI-2852 was used as a positive control, with its stock solution as the first dilution point, followed by a 3-fold dilution, making a total of 10+0...More data for this Ligand-Target Pair
TargetGTPase KRas [G12D]/Son of sevenless homolog 1 [564-1049](Human)
Shanghai Pharmaceuticals Holding Co.
US Patent
Shanghai Pharmaceuticals Holding Co.
US Patent
Affinity DataIC50: 247nMAssay Description:a) BI-2852 was used as a positive control, with its stock solution as the first dilution point, followed by a 3-fold dilution, making a total of 10+0...More data for this Ligand-Target Pair
Affinity DataIC50: 254nMAssay Description:a) BI-2852 was used as a positive control, with its stock solution as the first dilution point, followed by a 3-fold dilution, making a total of 10+0...More data for this Ligand-Target Pair
TargetGTPase KRas [G12D]/Son of sevenless homolog 1 [564-1049](Human)
Shanghai Pharmaceuticals Holding Co.
US Patent
Shanghai Pharmaceuticals Holding Co.
US Patent
Affinity DataIC50: 314nMAssay Description:a) BI-2852 was used as a positive control, with its stock solution as the first dilution point, followed by a 3-fold dilution, making a total of 10+0...More data for this Ligand-Target Pair
TargetGTPase KRas [G12D]/RAF proto-oncogene serine/threonine-protein kinase(Human)
Shanghai Pharmaceuticals Holding Co.
US Patent
Shanghai Pharmaceuticals Holding Co.
US Patent
Affinity DataIC50: 333nMAssay Description:a) BI-2852 was used as a positive control, with its stock solution as the first dilution point, followed by a 3-fold dilution, making a total of 10+0...More data for this Ligand-Target Pair
TargetGTPase KRas [G12D]/RAF proto-oncogene serine/threonine-protein kinase(Human)
Shanghai Pharmaceuticals Holding Co.
US Patent
Shanghai Pharmaceuticals Holding Co.
US Patent
Affinity DataIC50: 491nMAssay Description:a) BI-2852 was used as a positive control, with its stock solution as the first dilution point, followed by a 3-fold dilution, making a total of 10+0...More data for this Ligand-Target Pair
Affinity DataIC50: 559nMAssay Description:a) BI-2852 was used as a positive control, with its stock solution as the first dilution point, followed by a 3-fold dilution, making a total of 10+0...More data for this Ligand-Target Pair
